Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 17/20 | 0.54 |
| ▸ | TCF7L2 | Q9NQB0 | 17/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125240 | 0.85 | CTNNB1 (0.55) | CTNNB1TCF7L2APPACHESLC2A1 | |
| SCHEMBL3114944 | 0.83 | CTNNB1 (0.56) | CTNNB1TCF7L2APPACHESLC2A1 | |
| SCHEMBL3120956 | 0.81 | CTNNB1 (0.51) | CTNNB1TCF7L2APPSLC2A1 | |
| SCHEMBL3119458 | 0.80 | TUBB4A (0.46) | — | |
| SCHEMBL3115014 | 0.79 | PDE5A (0.52) | CTNNB1TCF7L2APPACHESLC2A1 | |
| SCHEMBL3106463 | 0.79 | CCNE2 (0.58) | CTNNB1TCF7L2APPACHESLC2A1 | |
| SCHEMBL3119112 | 0.78 | APP (0.61) | APPACHESLC2A1 | |
| SCHEMBL3115949 | 0.77 | HRH4 (0.54) | CTNNB1TCF7L2APPSLC2A1 | |
| SCHEMBL3125281 | 0.77 | APP (0.59) | CTNNB1TCF7L2APPACHESLC2A1 | |
| SCHEMBL3116762 | 0.77 | ACHE (0.78) | APPACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068197-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | claimed |
| US-20100068197-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068197-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MKI67, CCNI, CCNA1 | CTNNB1 1747/4885TCF7L2 2965/4885APP 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.